Culture plates shwoing the impact of Olaparib

Made:
2019 in United Kingdom
Two sets of six well cell culture plates showing the impact of the PARP inhibitor drug Olaparib on cancer cells with Two sets of six well cell culture plates showing the impact of the PARP inhibitor drug Olaparib on cancer cells with Two sets of six well cell culture plates showing the impact of the PARP inhibitor drug Olaparib on cancer cells with

Buy this image as a print 

Buy

License this image for commercial use at Science and Society Picture Library

License

Buy this image as a print 

Buy

License this image for commercial use at Science and Society Picture Library

License

Buy this image as a print 

Buy

License this image for commercial use at Science and Society Picture Library

License

Two sets of six well cell culture plates showing the impact of the PARP inhibitor drug Olaparib on cancer cells with
Science Museum Group
© The Board of Trustees of the Science Museum, London

Two sets of six well cell culture plates showing the impact of the PARP inhibitor drug Olaparib on cancer cells with
Science Museum Group
© The Board of Trustees of the Science Museum, London

Two sets of six well cell culture plates showing the impact of the PARP inhibitor drug Olaparib on cancer cells with
Science Museum Group
© The Board of Trustees of the Science Museum, London

Two demonstration six well cell culture plates showing the impact of the PARP inhibitor drug Olaparib on cancer cells with BRCA gene mutations, made by Professor Christopher Lord, Dr Rachel Bough, Dr Stephen Pettitt, at the Institute of Cancer Research, London, United Kingdom, 2019.

Scientists and clinicians at The Institute of Cancer Research and The Royal Marsden worked together for over ten years to develop this world first medicine. Olaparib was the first of a new class of cancer drugs called PARP inhibitors. PARPs are proteins that help damaged cells repair themselves. Researchers found that cancer cells with BRCA mutations rely on PARPs. Blocking PARP activity with Olaparib caused these cancer cells to die, as they were unable to repair themselves. This technique, which targets the inherent weakness of the cancer cell, is called synthetic lethality. The drug effectively targets and kills the cancer cells, but not healthy ones which means there are fewer side-effects.

Each blue dot on the plates is a group of cells with the BRCA mutation. The more Olaparib that is used, the fewer cancer cells survive.

Details

Category:
Laboratory Medicine
Object Number:
2020-145
Measurements:
overall: 85 mm x 128 mm
type:
cell culture plates
credit:
Professor Christopher Lord, Dr Rachel Bough, Dr Stephen Pettitt, The Institute of Cancer Research, London